Skip to main content

Table 1 LLC cell DHA metabolite concentration (ng/105 cell) determined by LC-MS/MS

From: Inhibition of lung cancer growth and metastasis by DHA and its metabolite, RvD1, through miR-138-5p/FOXC1 pathway

Oxylipin

LLC-GFP

LLC-GFP treat with DHA

LLC-mfat-1

10-HDoHE

0.34 ± 0.20

1072.73 ± 245.41**

736.22 ± 205.21**

10S,17S-DiHDoHE

NP

8.75 ± 3.54**

NP

11-HDoHE

NP

1300.73 ± 254.98**

NP

13-HDoHE

0.56 ± 0.39

734.25 ± 261.61**

575.98 ± 272.13**

14-HDoHE

0.46 ± 0.32

454.98 ± 197.20*

179.32 ± 92.18**

17-HDoHE

1.31 ± 0.74

1674.18 ± 492.10**

661.26 ± 133.4**

20-HDoHE

1.00 ± 0.63

2567.3 ± 438.31**

822.19 ± 212.35**

4-HDoHE

2.93 ± 1.10

5175.27 ± 475.64**

1634.9 ± 773.01**

7-HDoHE

0.59 ± 0.34

2020.17 ± 293.62**

536.16 ± 124.03**

8-HDoHE

2.57 ± 1.65

5847.24 ± 425.41**

1298.76 ± 235.18**

Maresin

NP

NP

NP

RvD1

NP

2.18 ± 0.59**

1.07 ± 0.32**

RvD2

NP

NP

NP

16,17-EDP

0.76 ± 0.55

1079.19 ± 333.12**

343.23 ± 83.43**

19,20-EDP

1.43 ± 0.42

3858.48 ± 419.96**

1131.8 ± 241.57**

  1. *P < 0.05, **P < 0.01 compared with LLC-GFP. Data are mean ± SD. NP No peak, CYP Cytochrome P450 enzymes, COX Cyclooxygenase, LOX Lipoxygenase, PG Prostaglandin